Next - Gen Hemostatic nano-powder: a theoretical framework for Nano Clot- safe

Uncontrolled haemorrhage remains a leading cause of mortality, particularly in trauma care and intraoperative settings. Existing haemostatic agents such as kaolin and chitosan have limitations including thermal tissue injury, infection risk, restricted internal applicability and delayed clot formation.

This paper proposes a theoretical haemostatic innovation, Nano Clot-SAFE, designed to achieve rapid haemostasis (≤3 seconds) with enhanced biocompatibility, antimicrobial properties and usability in both external and internal bleeding scenarios.

A conceptual formulation was developed based on an extensive review of 30 peer-reviewed studies. The proposed composition includes silica-alginate nanocomposites, microporous starch, tannin-functionalised cellulose and silver-doped zinc oxide nanoparticles. The formulation is designed for delivery via air-jet or aerosol mechanisms. Safety and usability considerations were informed by systems-based frameworks including the Swiss cheese model, human factors engineering and systems thinking.

Nano Clot-SAFE is theoretically designed to provide ultra-rapid clot formation, moisture resistance, antimicrobial action and surface adaptability, including compatibility with internal organs. The multi-component nano-powder formulation integrates multiple safety barriers aimed at reducing user error and enhancing clinical performance across trauma and surgical environments.

Nano Clot-SAFE represents a conceptual haemostatic framework rather than a finalised product. It offers potential applicability in emergency trauma care and surgical bleeding control. Further experimental validation and clinical testing are required. The proposed innovation highlights future directions in surgical technology development and trauma preparedness policy.